Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “PI3Kδ Inhibitor”

22 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 22 results

Large-scale testing (Phase 3)Ended earlyNCT04551066
What this trial is testing

To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)

Who this might be right for
MyelofibrosisPrimary MyelofibrosisPost Essential Thrombocythemia Myelofibrosis+1 more
Incyte Corporation 252
Testing effectiveness (Phase 2)Study completedNCT03144674
What this trial is testing

INCB050465 in Subjects With Relapsed or Refractory Marginal Zone Lymphoma (CITADEL-204)

Who this might be right for
Lymphoma
Incyte Corporation 110
Testing effectiveness (Phase 2)UnknownNCT05238064
What this trial is testing

Parsaclisib in Combination With CHOP in Participants With Previously Untreated PTCL

Who this might be right for
PI3Kδ InhibitorParsaclisibCHOP+1 more
Fudan University 30
Testing effectiveness (Phase 2)Looking for participantsNCT06421948
What this trial is testing

Linperlisib Combined With Chidamide in Patients With PTCL

Who this might be right for
Peripheral T-cell Lymphoma
Yanyan Liu 134
Testing effectiveness (Phase 2)Study completedNCT04434937
What this trial is testing

Open-Label Study of Parsaclisib, in Japanese Participants With Relapsed or Refractory Follicular Lymphoma (CITADEL-213)

Who this might be right for
Lymphoma
Incyte Biosciences Japan GK 42
Testing effectiveness (Phase 2)Study completedNCT04282018
What this trial is testing

Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab

Who this might be right for
Chronic Lymphocytic LeukemiaSmall Lymphocytic LymphomaFollicular Lymphoma+4 more
BeiGene 97
Testing effectiveness (Phase 2)Looking for participantsNCT06644183
What this trial is testing

Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)

Who this might be right for
LeukemiaRelapsed LeukemiaChronic Lymphocytic Leukemia+2 more
Jennifer R. Brown, MD, PhD 64
Early research (Phase 1)Active Not RecruitingNCT04328844
What this trial is testing

Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers

Who this might be right for
Solid Tumor, AdultNon-Hodgkin Lymphoma, AdultNSCLC+2 more
iOnctura 210
Large-scale testing (Phase 3)Ended earlyNCT04551053
What this trial is testing

To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)

Who this might be right for
MyelofibrosisPrimary MyelofibrosisPost Essential Thrombocythemia Myelofibrosis+1 more
Incyte Corporation 177
Testing effectiveness (Phase 2)Study completedNCT03126019
What this trial is testing

INCB050465 in Relapsed or Refractory Follicular Lymphoma

Who this might be right for
Lymphoma
Incyte Corporation 126
Early research (Phase 1)Study completedNCT03424122
What this trial is testing

INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)

Who this might be right for
B-cell Lymphoma
Incyte Corporation 50
Testing effectiveness (Phase 2)Active Not RecruitingNCT04783415
What this trial is testing

Acalabrutinib, Umbralisib, and Ublituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma

Who this might be right for
Mantle Cell Lymphoma
City of Hope Medical Center 12
Testing effectiveness (Phase 2)Study completedNCT02998476
What this trial is testing

Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202)

Who this might be right for
Lymphoma
Incyte Corporation 60
Post-approval studies (Phase 4)Ended earlyNCT02739360
What this trial is testing

Roll Over Study to Provide Idelalisib to Participants Previously Treated With the Investigational PI3Kδ Inhibitor, GS-9820

Who this might be right for
Lymphoid Malignancies
Gilead Sciences 3
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06799676
What this trial is testing

A Phase Ib/II Clinical Study on the Application of Linperlisib Combined with the VRD Regimen in Newly Diagnosed Patients with Multiple Myeloma

Who this might be right for
Newly Diagnosed Multiple Myeloma
Fuling Zhou 42
Early research (Phase 1)Study completedNCT03688152
What this trial is testing

A Safety and Tolerability Study of INCB053914 in Combination With INCB050465 in Diffuse Large B-Cell Lymphoma

Who this might be right for
Relapsed Diffuse Large B-Cell LymphomaRefractory Diffuse Large B-Cell Lymphoma
Incyte Corporation 9
Testing effectiveness (Phase 2)Study completedNCT03627065
What this trial is testing

INCB050465 in Primary Sjögren's Syndrome

Who this might be right for
Primary Sjögren's Syndrome
Incyte Corporation 10
Testing effectiveness (Phase 2)Ended earlyNCT04809467
What this trial is testing

A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL)

Who this might be right for
Chronic Lymphocytic LeukemiaNon Hodgkin Lymphoma
Incyte Corporation 54
Testing effectiveness (Phase 2)Study completedNCT03235544
What this trial is testing

INCB050465 in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a Bruton's Tyrosine Kinase (BTK) Inhibitor

Who this might be right for
Lymphoma
Incyte Corporation 162
Testing effectiveness (Phase 2)Study completedNCT04298879
What this trial is testing

IBI376 in Patients With Relapsed or Refractory Follicular Lymphoma/Marginal Zone Lymphoma

Who this might be right for
Indolent Non-hodgkin Lymphoma
Innovent Biologics (Suzhou) Co. Ltd. 81
Load More Results